TGFbeta affects collagen cross-linking independent of chondrocyte phenotype but strongly depending on physical environment.
Transforming growth factor beta (TGFbeta) is often used in cartilage tissue engineering to increase matrix formation by cells with various phenotypes. However, adverse effects of TGFbeta, such as extensive crosslinking in cultured fibroblasts, have also been reported. Our goal was to study effects of TGFbeta on collagen cross-linking and evaluating the role of cellular phenotype and physical environment. We therefore used four different cell populations in two very different physical environments: primary and expanded chondrocytes and fibroblasts embedded in alginate gel and attached to tissue culture plastic. Matrix production, collagen cross-linking, and alpha-smooth muscle actin (alphaSMA) were analyzed during 4 weeks with or without 2.5 ng/ mL TGFbeta2. TGFbeta2 did not affect collagen deposition by primary cells. In expanded cells, TGFbeta2 increased collagen deposition. Chondrocytes and fibroblasts in monolayer produced more collagen cross-links with TGFbeta2. In alginate, primary and expanded cells displayed an unexpected decrease in collagen cross-linking with TGFbeta2. alphaSMA was not present in alginate cultures and barely upregulated by TGFbeta2. Organized alphaSMA fibers were present in all monolayer cultures and became more pronounced with TGFbeta2. This study demonstrates that the physical environment determined by the substrate used co-determines the response of cells to TGFbeta. The presence of mechanical stress, determined with alphaSMA-staining, is probably responsible for the increase in collagen cross-linking upon addition of TGFbeta.
Bastiaansen-Jenniskens
Yvonne Maria
YM
Department of Orthopaedics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Koevoet
Wendy
W
De Bart
Anton C W
AC
Zuurmond
Anne-Marie
AM
Bank
Ruud A
RA
Verhaar
Jan A N
JA
DeGroot
Jeroen
J
van Osch
Gerjo J V M
GJ
D000199:Actins / Q000378:metabolism; D000818:Animals; D002417:Cattle; D002478:Cells, Cultured; D019902:Chondrocytes / Q000166:cytology* / Q000187:drug effects*; D003094:Collagen / Q000378:metabolism*; D024042:Collagen Type I / Q000378:metabolism; D024043:Collagen Type II / Q000378:metabolism; D003432:Cross-Linking Reagents / Q000378:metabolism*; D004247:DNA / Q000032:analysis; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D007150:Immunohistochemistry; D009130:Muscle, Smooth / Q000378:metabolism; D010641:Phenotype; D055758:SOX9 Transcription Factor / Q000235:genetics / Q000378:metabolism; D053781:Transforming Growth Factor beta2 / Q000494:pharmacology*
D000199:Actins; D024042:Collagen Type I; D024043:Collagen Type II; D003432:Cross-Linking Reagents; D055758:SOX9 Transcription Factor; D053781:Transforming Growth Factor beta2; D003094:Collagen; D004247:DNA